The roles of microRNAs in the progression of castration-resistant prostate cancer

被引:33
|
作者
Kojima, Satoko [1 ]
Goto, Yusuke [2 ]
Naya, Yukio [1 ]
机构
[1] Teikyo Univ, Dept Urol, Chiba Med Ctr, 3426-3 Anesaki, Ichihara, Chiba 2990111, Japan
[2] Chiba Univ, Dept Funct Genom, Grad Sch Med, Chiba, Japan
关键词
EPITHELIAL-MESENCHYMAL TRANSITION; ANDROGEN RECEPTOR; TUMOR-SUPPRESSOR; DOWN-REGULATION; CIRCULATING MICRORNAS; EXPRESSION SIGNATURE; CELL-PROLIFERATION; BIOCHEMICAL RECURRENCE; MIR-222; EXPRESSION; P53; SUPPRESSES;
D O I
10.1038/jhg.2016.69
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Prostate cancer (PCa) is one of the leading causes of cancer-related death in men. PCa is androgen-dependent, and androgen-deprivation therapy is effective for first-line hormonal treatment, but the androgen-independent phenotype of PCa eventually develops, which is difficult to treat and has no effective cure. Recently, microRNAs have been discovered to have important roles in the initiation and progression of PCa, suggesting their use in diagnosis, predicting prognosis and development of treatment for castration-resistant PCa (CRPC). Understanding the networks of microRNAs and their target genes is necessary to ascertain their roles and importance in the development and progression of PCa. This review summarizes the current knowledge about microRNAs regulating PCa progression and elucidates the mechanism of progression to CRPC.
引用
收藏
页码:25 / 31
页数:7
相关论文
共 50 条
  • [21] Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
    Lin, H-M
    Castillo, L.
    Mahon, K. L.
    Chiam, K.
    Lee, B. Y.
    Nguyen, Q.
    Boyer, M. J.
    Stockler, M. R.
    Pavlakis, N.
    Marx, G.
    Mallesara, G.
    Gurney, H.
    Clark, S. J.
    Swarbrick, A.
    Daly, R. J.
    Horvath, L. G.
    BRITISH JOURNAL OF CANCER, 2014, 110 (10) : 2462 - 2471
  • [22] ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer
    J R Gsponer
    M Braun
    V J Scheble
    T Zellweger
    A Bachmann
    S Perner
    T Vlajnic
    M Srivastava
    S-H Tan
    A Dobi
    I A Sesterhenn
    S Srivastava
    L Bubendorf
    C Ruiz
    Prostate Cancer and Prostatic Diseases, 2014, 17 : 126 - 131
  • [23] ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer
    Gsponer, J. R.
    Braun, M.
    Scheble, V. J.
    Zellweger, T.
    Bachmann, A.
    Perner, S.
    Vlajnic, T.
    Srivastava, M.
    Tan, S-H
    Dobi, A.
    Sesterhenn, I. A.
    Srivastava, S.
    Bubendorf, L.
    Ruiz, C.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2014, 17 (02) : 126 - 131
  • [24] Upregulation of erythropoietin and erythropoietin receptor in castration-resistant progression of prostate cancer
    Ye, Chen
    Chen, Guang-Hua
    Chen, Xin
    Qin, Sheng-Fei
    Shi, Min-Feng
    Zhou, Tie
    ASIAN JOURNAL OF ANDROLOGY, 2020, 22 (04) : 422 - 426
  • [25] Darolutamide For Castration-Resistant Prostate Cancer
    Bastos, Diogo A.
    Antonarakis, Emmanuel S.
    ONCOTARGETS AND THERAPY, 2019, 12 : 8769 - 8777
  • [26] Diethylstilbestrol in castration-resistant prostate cancer
    Wilkins, Anna
    Shahidi, Mehdi
    Parker, Chris
    Gunapala, Ranga
    Thomas, Karen
    Huddart, Robert
    Horwich, Alan
    Dearnaley, David
    BJU INTERNATIONAL, 2012, 110 (11B) : E727 - E735
  • [27] Abiraterone and castration-resistant prostate cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2013, 14 (02): : E48 - E48
  • [28] Immunotherapy for Castration-Resistant Prostate Cancer
    Sonpavde, Guru
    Kantoff, Philip W.
    UROLOGIC CLINICS OF NORTH AMERICA, 2012, 39 (04) : 465 - +
  • [29] Chemotherapy for castration-resistant prostate cancer
    Berthold, D.
    ONKOLOGIE, 2011, 34 : 12 - 12
  • [30] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438